Redeye comments on the recent news of Integrum’s plans of supporting the US Department of Veterans Affairs with its OPRA implant system. The announcement supports our thesis, and we reiterate our Base Case at SEK 110 per share, offering an attractive upside from current levels.
LÄS MER